RAPP (Rapport Therapeutics) Total Liabilities: $26.09 Mil (As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Total Liabilities?

Rapport Therapeutics RAPP -0.60% 14 Total Liabilities is $26.09 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Rapport Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $26.09 Mil.

Rapport Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($23.71 Mil) to Dec. 2025 ($27.78 Mil) but then declined from Dec. 2025 ($27.78 Mil) to Mar. 2026 ($26.09 Mil).

Rapport Therapeutics's annual Total Liabilities declined from Dec. 2023 ($181.06 Mil) to Dec. 2024 ($9.51 Mil) but then increased from Dec. 2024 ($9.51 Mil) to Dec. 2025 ($27.78 Mil).

Rapport Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Total Liabilities Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
41.67 181.06 9.51 27.78

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.22 21.98 23.71 27.78 26.09
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rapport Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.049+(8.729+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=27.78

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=512.431-484.653
=27.78

Rapport Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.897+(8.188+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.09

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=497.597-471.512
=26.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $26.09 Mil mean?
Rapport Therapeutics (RAPP) has a Total Liabilities of $26.09 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Total Liabilities too high?
Rapport Therapeutics' current Total Liabilities is $26.09 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Total Liabilities compare to SION and TYRA?
Rapport Therapeutics' Total Liabilities of $26.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rapport Therapeutics and its competitors. Rapport Therapeutics's current Total Liabilities is $26.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Total Liabilities of $26.09 Mil. The current Total Liabilities is $26.09 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Total Liabilities is $26.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price